Efficacy of Dexrazoxane in Preventing Anthracycline Cardiotoxicity in Breast Cancer

2019159 citationsJournal Articlegold Open Access

Authors

Ariane Vieira Scarlatelli Macedo · Universidade Federal de Minas Gerais

Ludhmila Abrahão Hajjar

Alexander R. Lyon · Royal Brompton Hospital

Bruno Ramos Nascimento · Universidade Federal de Minas Gerais

Alessandro Putzu · University Hospital of Geneva

Lorenzo Rossi · Institute of Oncology Research

Rafael Brant Costa

Giovanni Landoni

Abstract

Dexrazoxane reduced the risk of clinical heart failure and cardiac events in patients with breast cancer undergoing anthracycline chemotherapy with or without trastuzumab and did not significantly impact cancer outcomes. However, the quality of available evidence is low, and further randomized trials are warranted before the systematic implementation of this therapy in clinical practice.

Topics & Keywords

Chemotherapy-induced cardiotoxicity and mitigation Cancer-related cognitive impairment studies Cancer Treatment and Pharmacology

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: JACC CardioOncology

Volume 1, Issue 1, pp. 68-79

DOI: 10.1016/j.jaccao.2019.08.003

Field-Weighted Citation Impact: 6.92